- Who we areWho we are
We are a biotechnology company committed to helping address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- What we doWhat we do
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Blog
Novavax CEO to Discuss Future of Global Vaccine Business as Part of Panel of Industry Leaders at 2018 BIO International Convention
Gaithersburg, MD, [May 31, 2018] – Novavax, Inc. (Nasdaq: NVAX) today announced that Stanley C. Erck, President and Chief Executive Officer, will be part of a panel of vaccine industry leaders at the 2018 BIO International Convention in Boston, Massachusetts scheduled for Tuesday, June 5 at 12:15 p.m. EST. The panelists will discuss the future of the global vaccine business, including the opportunities and challenges facing vaccine developers and the importance of continued innovation in vaccines.
| Title: | “The Global Vaccine Business: A View from the Top” |
| Date and Time: | Tuesday, June 5, 12:15 p.m. |
| Moderator: | Jacqueline Keith, MA, PhD, President, J Keith Consulting Group |
| Panelists: | Stanley Erck, President and Chief Executive Officer, Novavax David Loew, Head, Global Commercial Operations, Sanofi Pasteur Michael Nally, President, Merck Vaccines Gordon Naylor, President, Seqirus Rajeev Venkayya, MD, President, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited |
About Novavax
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and NanoFlu vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of its efforts to improve global health. For more information, please visit www.novavax.com.
Follow us on Twitter (@Novavaxinc).
Follow us on LinkedIn (NOVAVAX INC).
Forward-Looking Statements
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contact:
Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
